Steven Kafka, Jason Ryan, Daniel O'Day, and more

Mar 23, 2015

Foundation Medicine announced four executive promotions and the hiring of a global marketing senior vice president. Additionally, it proposed changes to its board in connection to its strategic collaboration with Roche. 

Those who were promoted include Steven Kafka, Jason Ryan, Elaine Labrecque, and Sarah Larson. Kafka has been promoted to president. He currently is Foundation Medicine's COO and will maintain that position. He joined the company in 2013 and was previously COO and CFO at Aileron Therapeutics. 

Ryan was promoted to CFO. He joined Foundation Medicine in 2011 and was responsible for building the firm's public company financial infrastructure. He previously led the finance and strategic planning functions at companies that include Taligen Therapeutics and Genomics Collaborative. 

Labrecque was promoted to senior VP of operations. She joined the company in 2013 as VP of laboratory operations from ConVerge Diagnostic Services where she was COO. She also was at Quest Diagnostics for 20 years. 

Larson was promoted to senior VP human resources. She has been at Foundation Medicine for four years and was one of the company's first employees. She previously led the global human resources function at CombinatoRx. 

Foundation Medicine also hired Matt Franklin to the new created role of senior vice president of global marketing. He will report to Chief Commercial Officer David Daly. Franklin was most recently VP of global marketing for Boston Scientific's interventional cardiology division. 

The Cambridge, Mass.-based cancer molecular diagnostics firm additionally proposed changes to its board, including expanding it to nine directors in connection to a $1.2 billion stake that Roche plans to take in Foundation Medicine. 

As part of the expansion of Foundation Medicine's board, Roche can designate three candidates to the firm's board. This week, Roche identified the designees as Daniel O'Day, Sandra Horning, and Michael Varney. 

O'Day is COO of Roche Pharmaceuticals. Horning is global head of product development and CMO of Roche/Genentech, and Varney is head of Genentech Research and Early Development. 

Foundation Medicine's current board members are CEO Michael Pellini, Alexis Borisy, Evan Jones, David Schenkein, Krishna Yeshwant, and Brook Byers, who is expected to leave the board upon the completion of the Roche transaction, anticipated to occur in the second quarter of 2015. The final board seat will be filled after the close of the deal with an independent director mutually agreed upon by Foundation Medicine and Roche.

More Like This

Apr 26, 2017

Rich Gray

N-of-One has appointed Rich Gray as VP of business development. In this position, he will lead both direct and channel sales teams to further develop channel partnerships to provide clinical interpretation on a broader scale. Gray joins N-of-One after serving various executive sales and market roles at organization such as Altos, now part of Flatiron Health; IntelliDose division of IntrinsiQ, now a division of AmerisourceBergen; and Medical Systems Management, now part of Optum.

Apr 26, 2017

Jamie L’Heureux

Progeny Genetics, a Delray Beach, Fla-based subsidiary of Ambry Genetics, has promoted Jamie L’Heureux to CEO. L'Heureux had been a software project manager at the company since 2014 and was a contractor for Progeny for two years before than. She has a total of 12 years of experience as a board-certified genetic counselor.

Apr 25, 2017

Vicki DiFrancesco

Xifin has appointed Vicki DiFrancesco its chief strategy officer. DiFrancesco has more than 25 years of experience in executive leadership positions and was most recently president and CEO of Pathology Inc., a women's health laboratory acquired by Laboratory Corporation of America last year. 

Apr 20, 2017

Bill Bonello

NeoGenomics has appointed Bill Bonello as VP, treasurer, and director of corporate development. Prior to joining NeoGenomics, Bonello served as senior research analyst at Craig Hallum Capital Markets, and as senior research analyst for RBC Capital Markets. He has also served as senior VP of investor relations for Laboratory Corporation of America, managing director of equity research at Wachovia Capital Markets, and managing director of equity research at Piper Jaffray.

Apr 18, 2017

Mark Boguski

Inspirata has appointed Mark Boguski to the role of chief medical officer for precision medicine. He will oversee strategic planning and implementation of the firm's precision medicine solutions. Prior to joining Inspirata in September 2016, Boguski served as CMO and cofounder of Precision Medicine Network, where he created a molecular oncology knowledge visualization and decision support platform called Crosswalk Insight: Oncology.

Apr 17, 2017

Jordan Hubbard

Jordan Hubbard has joined Two Pore Guys as vice president of engineering, where he will oversee the development of software and hardware for the company's nanopore-based single-molecule biosensor. Previously, Hubbard served as a manager and director of engineering at Apple, and headed up the FreeBSD project, an open-source UNIX variant that became a core technology in Apple's products.

Apr 13, 2017

David Schenkein

David  Schenkein has told the board of Foundation Medicine he will not stand for reelection during the company's annual shareholders' meeting. He will retire from the board effective as of the date of the meeting. Schenkein is a member of the audit committee.
Apr 12, 2017

Patrick Balthrop

Agendia has appointed Patrick Balthrop, former CEO of Luminex, as non-executive chairman. Balthrop is a director at Oxford Immunotec, Personalis, and Concert Genetics. He's also an advisor to Water Street Healthcare Partners and the Founding Principal of Apalachee Ventures, an investment and advisory firm. 

Apr 05, 2017

Alister Reynolds

Alister Reynolds has agreed to become CEO of SomaLogic. He is replacing Byron Hewett, who is stepping down. Reynolds has been on the company's board since 2003, and has held senior executive positions at Quest Diagnostics and its predecessor Corning.

Apr 05, 2017

Vishal Sikri

Vishal Sikri was appointed the general manager of Biocartis' US subsidiary, Biocartis US. Sikri was managing director and VP of commercial operations at Sysmex Inostics, the molecular diagnostics division of Sysmex, where he held other various roles. Prior to Sysmex, he held different senior product management positions at Abbott Laboratories. 

Apr 04, 2017

Erik Phelps

Tempus has hired Erik Phelps as executive VP and general counsel. He will be responsible for general corporate matters, strategy, and several other legal areas. Phelps comes to Tempus from electronic health records maker Epic Systems, where he also served as general counsel. He holds a JD from George Washington University Law School.

Apr 03, 2017

James Heath

The Institute for Systems Biology named James Heath its new president, effective January 2018. The current President and ISB Cofounder Lee Hood will remain on the institute's board. Heath is the Elizabeth W. Gilloon professor of chemistry at the California Institute of Technology, and a professor of molecular and medical pharmacology and codirector of the Parker Institute for Cancer Immunotherapy at the University of California, Los Angeles. He also is director of the NanoSystems Biology Cancer Center, which is funded by the National Cancer Institute. 

Mar 30, 2017

Joshua LaBaer

Joshua LaBaer has been appointed the executive director of the Biodesign Institute at Arizona State University, effective April 1. He was formerly at Harvard before joining ASU in 2009 to lead personalized medicine efforts at the institute as the university's first Virginia G. Piper Chair of Personalized Medicine, and director of the Biodesign Virginia G. Piper Center for Personalized Diagnostics. 

Mar 30, 2017

Michael Knell, Anthony Mattacchione

Bruker VP of Finance and Chief Accounting Officer Michael Knell announced he is resigning from the firm, effective April 21, in order to pursue other opportunities. Bruker CFO and Senior VP Anthony Mattacchione has assumed Knell's responsibilities as the company's principal accounting officer.

Mar 29, 2017

Alex Forrest-Hay

Metabolon has appointed Alex Forrest-Hay as VP of population health. In this position, Forrest-Hay will focus on the company's plans to expand its efforts to apply metabolomics to large population health studies. Before joining Metabolon, Forrest-Hay served as director of business development at Affymetrix. Prior to his work at Affymetrix, he served as a genomics specialist at Beckman Coulter and worked as a researcher at the University of Keele.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.